Circulation-Heart Failure

Papers
(The H4-Index of Circulation-Heart Failure is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy412
Trends in 30- and 90-Day Readmission Rates for Heart Failure138
Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis119
Polypharmacy in Older Adults Hospitalized for Heart Failure110
Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure98
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy83
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy66
Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction59
Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations59
Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock55
Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients52
Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction49
Excess 30-Day Heart Failure Readmissions and Mortality in Black Patients Increases With Neighborhood Deprivation47
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial46
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure46
Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy42
Metabolomic Profiles and Heart Failure Risk in Black Adults: Insights From the Jackson Heart Study41
Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota40
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure40
Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure38
Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction38
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review38
Global Differences in Heart Failure With Preserved Ejection Fraction37
Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database36
NAD + Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy36
Extracardiac Abnormalities of Preload Reserve36
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design35
Clinical Characteristics and Predictors of In-Hospital Mortality in Patients With Cardiogenic Shock: Results From the RESCUE Registry35
Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes35
Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy35
Disparity in the Setting of Incident Heart Failure Diagnosis35
Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort34
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States34
Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy33
0.035383939743042